Skip to main content

EFICACIA DE NUEVAS PAUTAS DE TRATAMIENTO ANTIBIOTICO DE LA ENDOCARDITIS ENTEROCOCICA EVALUADAS IN VITRO Y EN EL MODELO DE ENDOCARDITIS EXPERIMENTAL.

PI17/01251

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA CLINIC
Execution centre HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-faecalis and Non-faecium Enterococcal Isolates With/Without VanC Phenotype, Clinical Implications for Infective Endocarditis

  • García-González, Javier
  • Cañas, María Alexandra|||0000-0002-0521-7204
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Hernández Meneses, Marta|||0000-0001-9991-1127
  • Verdejo, Miguel Ángel|||0000-0001-7870-0515
  • Bodro, Marta|||0000-0002-0520-8279
  • Díez de los Ríos, Javier
  • Gasch, Oriol|||0000-0001-8518-458X
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Falces, Carles|||0000-0002-3483-3786
  • Perissinotti, Andrés|||0000-0003-4190-2425
  • Vidal, Bárbara
  • Quintana, Eduard|||0000-0002-5386-7463
  • Moreno Camacho, Asunción|||0000-0001-6382-0039
  • Piquet, Maria
  • Roca, Ignasi|||0000-0002-1800-1576
  • Fernandez-Pittol, Mariana|||0000-0002-1685-7127
  • San José-Villar, Sol M.
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Miró, José M.|||0000-0001-8057-7755
(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-faecalis/non-faecium enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time-kill curves with standard (ISI) and high (IHI) inocula were performed to test VanC isolates [3 E. casseliflavus (ECAS) and 1 E. gallinarum (EGALL)] and non-VanC isolates [1 E. durans (EDUR), 1 E. hirae (EHIR) and 1 E. raffinosus (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?

  • Bierge, Paula|||0000-0003-0917-3445
  • Gómez-Sánchez, Inmaculada|||0000-0002-4255-0882
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Sánchez-Osuna, Miquel|||0000-0001-5267-4814
  • Capilla, Silvia|||0000-0002-7274-2973
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Espasa, Mateu|||0000-0003-4822-1024
  • Novais, Carla|||0000-0002-3826-6731
  • Miró, José M.|||0000-0001-8057-7755
  • Pich, Oscar Q.|||0000-0003-3561-630X
  • Gasch, Oriol|||0000-0001-8518-458X
Objectives: Enterococcus faecium, a significant hospital associated pathogen, poses substantial treatment challenges. While combinations of ampicillin with cephalosporins are first-line therapies to treat Enterococcus faecalis high-mortality-rates infections, their efficacy against ampicillin-susceptible E. faecium (ASEfm) is less clear. This study evaluates the effectiveness of combining ampicillin with ceftriaxone or ceftaroline against ASEfm strains. Methods: Ten ASEfm bloodstream isolates from complicated infections were analyzed. Susceptibility to several antibiotics, including ceftriaxone, ceftaroline, and cefotaxime, was determined using standard methods. Time-kill assays were conducted to assess the synergistic and additive effects of ampicillin in combination with ceftriaxone or ceftaroline. Results: Time-kill studies revealed that ampicillin combined with ceftaroline demonstrated synergistic and/or additive effects in 7 out of 10 strains analyzed. In contrast, ampicillin combined with ceftriaxone showed less pronounced synergy, with only 3 out of 10 strains exhibiting synergistic and/or additive effects. Conclusions: Our findings indicate that ampicillin combined with ceftaroline, or ceftriaxone provides synergistic activity against some but not all ASEfm clinical isolates. The observed synergy suggests that these combinations could offer a potential therapeutic option for challenging ASEfm infections.